Hypermutation takes the driver's seat

Genome Medicine

Volumn 7, Issue 1, 2015, Pages

  Schlesner, Matthias ^a   Eils, Roland ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DNA POLYMERASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AMINO ACID SEQUENCE; ARTICLE; B CELL LYMPHOMA; CANCER GROWTH; CANCER THERAPY; CELL FUNCTION; CHILDHOOD CANCER; CHILDHOOD LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; CUTANEOUS MELANOMA; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; DNA SYNTHESIS; GENOME; GENOME ANALYSIS; HUMAN; LUNG CANCER; MALIGNANT TRANSFORMATION; MISMATCH REPAIR; MUTATION RATE; PRIORITY JOURNAL; SOMATIC MUTATION;

EID: 84925587669     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/s13073-015-0159-x     Document Type: Article

References (8)

1. Andersson AK, Ma J, Wang J, Chen X, Gedman AL, Dang J, et al. The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias. Nat Genet. 2015. doi:10.1038/ng.3230.
2. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499:214-8.
3. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415-21.
4. Jäger N, Schlesner M, Jones DT, Raffel S, Mallm JP, Junge KM, et al. Hypermutation of the inactive X chromosome is a frequent event in cancer. Cell. 2013;155:567-81.
5. Shlien A, Campbell BB, de Borja R, Alexandrov LB, Merico D, Wedge D, et al. Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. Nat Genet. 2015;47:257-62.
6. Supek F, Lehner B. Differential DNA mismatch repair underlies mutation rate variation across the human genome. Nature. 2015. doi:10.1038/nature14173.
7. Aksoy BA, Demir E, Babur Ö, Wang W, Jing X, Schultz N, et al. Prediction of individualized therapeutic vulnerabilities in cancer from genomic profiles. Bioinformatics. 2014;30:2051-9.
8. Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, et al. Classification of current anticancer immunotherapies. Oncotarget. 2014;5:12472-508.